Congratulations to our student, Dina Farran
May 22, 2024
View Dina's Abstract
We are delighted to share that one of our EPSRC DRIVE-Health CDT students and PhD candidate at the IoPPN, Dina Farran, has been awarded 1st prize presentation at the recent Royal College of Psychiatrists Faculty of Liaison Psychiatry annual conference earlier this month. Dina is working under the supervision of Professor Fiona Gaughran and Professor Mark Ashworth and is about to submit her thesis at the end of this month.
In the presentation, Dina summarised her PhD project consisting of a literature review, 2 observational studies, an intervention and 2 qualitative studies. Dina provides further detail below.
Background
Atrial fibrillation (AF), the most prevalent cardiac arrhythmia, is associated with an increased risk of stroke contributing to heart failure and death. In this project, we aim to improve patient safety by screening for stroke risk among people with AF and co-morbid mental illness.
Methods
(a) Conducted a systematic review and meta-analysis on prevalence, management, and outcomes of AF in people with Serious Mental Illness (SMI) versus the general population.
(b) Evaluated oral anticoagulation (OAC) prescription trends in people with AF and co-morbid SMI in King’s College Hospital.
(c) Identified the recorded rates of OAC prescription among people with AF and various mental illnesses and evaluated the association between mental illness severity and OAC prescription in eligible patients in South London and Maudsley (SLaM) NHS Foundation Trust.
(d) Implemented an electronic clinical decision support system (eCDSS) consisting of a visual prompt on patient electronic Personal Health Record to screen for AF-related stroke risk in three Mental Health of Older Adults wards at SLaM.
(e) Assessed the feasibility and acceptability of the eCDSS by qualitatively investigating clinicians’ perspective of the potential usefulness of the eCDSS (pre-intervention) and their experiences and their views regarding its impact on clinicians and patients (post-intervention).
Results
(a) People with SMI had low reported rates of AF. AF patients with SMI were less likely to receive OAC than the general population. When receiving warfarin, people with SMI, particularly bipolar disorder, experienced poor anticoagulation control compared to the general population. Meta-analysis showed that SMI was not significantly associated with an increased risk of stroke or major bleeding when adjusting for underlying risk factors.
(b) Among AF patients having a high stroke risk, those with co-morbid SMI were less likely than non-SMI patients to be prescribed any OAC, particularly warfarin (but not DOACs). However, there was no evidence of a significant difference between the two groups since 2019.
(c) Adjusting for age, sex, stroke and bleeding risk scores, patients with AF and co-morbid SMI were less likely to be prescribed any OAC compared to those with dementia, substance use disorders or common mental disorders. Among AF patients with co-morbid SMI, warfarin was less likely to be prescribed to those having alcohol or substance dependency, serious self-injury, hallucinations or delusions and activities of daily living impairment.
(d) Clinicians were asked to confirm the presence of AF, clinically assess stroke and bleeding risks, record risk scores in clinical notes and refer patients at high risk of stroke to OAC clinics.
(e) Clinicians reported that the eCDSS saved time, prompted them towards guidelines, boosted their confidence, and identified patients at risk. Perceived barriers to using the tool included low admission rate of AF cases, low or insufficient visibility of the alert/awareness of the tool, and impact of the eCDSS on workload.
Conclusions
This study presents a unique opportunity to quantify AF patients with mental illness who are at high risk of severe outcomes, using electronic health records. This has the potential to improve health outcomes and therefore patients' quality of life.
Share
We are delighted to welcome Luis Garcia-Gancedo , Executive Director and Head of Digital Medicine at GSK , to speak at our symposium and partner showcase next month. Luis will deliver his talk “Digital Medicine in Clinical Development: Innovation at the Industry-Academia Interface " Abstract: Digital Medicine is transforming clinical trials, with wearable devices, digital endpoints, decentralised trial technologies and AI-driven insights already integrated into many clinical development programmes. This presentation will provide an overview of the current landscape and will discuss the opportunity for industry-academia collaborations to overcome existing barriers (including evidence generation to support validation and regulatory acceptance) to propel the field forward for the benefit of patients. Date and Time: Thursday 11 June 2026, 10:00 hrs (BST) Location: The Science Gallery London, Guy's Campus Tickets are free, please register as spaces are limited : https://buytickets.at/kingsepsrcdrivehealthcentrefordoctoraltrainingindatadrivenhealth/2143742 Biography Luis Garcia-Gancedo is an Executive Director and Head of Digital Medicine at GSK. In this role, he streamlines the consideration of digital health technologies in GSK’s respiratory, immunology and inflammation clinical trials, transitioning from an opportunistic to a strategic approach for developing and deploying novel digital solutions that address key clinical development challenges. Prior to his current role, he was with AstraZeneca, GSK, and the University of Cambridge. Luis holds a BSc/MSc in Physics, a PhD in Engineering and an Executive MBA.
Bridging Academia and Industry: Turning Health Data into Health Solutions Please join us for the EPSRC DRIVE‑Health CDT Summer Symposium & Partner Showcase 2026 , a two‑day event dedicated to bridging academia and industry and accelerating the journey from health data research to real‑world solutions. This year’s theme, “Bridging Academia and Industry: Turning Health Data into Health Solutions", brings together our vibrant community of students, King’s academics, industry partners, clinicians and policymakers to explore how collaboration can unlock new insights, innovation and impact across health and care. Event details 📅 11 & 12 June 2026 📍 Science Gallery London, Guy’s Campus, King’s College London, Great Maze Pond, London SE1 9GU Timings: ⏰ 10:00–16:00 each day ☕ Refreshments available from 09:30 👉 Please be seated by 09:50 for a prompt 10:00 start Please secure your place here: Register Now Programme highlights KEYNOTE ✨ Dr Luis Garcia‑Gancedo , Executive Director & Head of Digital Medicine – Respiratory, Immunology & Inflammation, GSK INTERACTIVE DEBATE ✨ Student‑led interactive debate exploring AI within the context of the event theme: “Bridging Academia and Industry: Turning Health Data into Health Solutions.” PANEL DISCUSSION & POSTER JUDGING ✨ “What does industry actually need from health data PhDs - and how can industry partner with academia for maximum impact?” Panelists confirmed so far: Dr Laura Acqualagna , Director of AI/ML Engineering, GSK R&D Dr Chris Callaghan , Consultant Transplant Surgeon, Guy’s Hospital Dr Nina Sesto , CEO & Co‑Founder, MEGI Health Dr Srinivasan Vairavan , Director of Data Science & Digital Health, JNJ Innovative Medicine R&D, and Visiting Adjunct Faculty, King’s College London Dr Nicolas Huber , Director, King’s Innovation Catalyst PLUS ✨ Student lightning talks (across both days) ✨ 3‑minute Student Spotlight Slides (across both days) ✨ Poster showcase & networking session (Friday) ✨ Prizes for outstanding contributions (Friday) Please secure your place here: Register Now If you are no longer able to attend the event, please email drive-health-cdt@kcl.ac.uk so that we can reallocate to our waiting list.
